Diagnosis and Staging of Patients with Ovarian Cancer

Objectives

Provide a national, evidence-based clinical framework for the diagnosis and staging of adults aged over 18 years with suspected, newly diagnosed or recurrent ovarian cancer, supporting safe, effective, high-quality and consistent care across Irish health services.[1][2][3]The guideline seeks to reduce unwarranted clinical variation, improve patient outcomes and reduce morbidity and mortality by promoting interventions with proven benefit, discouraging ineffective interventions, and integrating research evidence, clinical expertise and patient preferences.[4][3]

• Improve early diagnosis and accurate staging, recognising that outcomes are substantially better for disease diagnosed at stages I or II than at stages III or IV.[5]
• Centralise cancer surgery in approved specialist centres to improve quality and outcomes, consistent with the National Cancer Strategy 2017-2026 target for 95% of cancer surgery to be undertaken in approved centres.[5]
• Apply validated diagnostic pathways, including combined transabdominal and transvaginal ultrasound interpreted using International Ovarian Tumour Analysis simple rules with clinical assessment; magnetic resonance imaging for indeterminate masses when results affect management; and contrast-enhanced computed tomography of the thorax, abdomen and pelvis for staging.[6][7][8]
• Strengthen diagnosis and sub-typing through adequate histological specimens, morphology, immunohistochemistry and correlation of clinical, radiological, pathological and cytological findings within multidisciplinary teams.[9][10][11]
• Provide germline testing appropriate to tumour subtype, including BRCA testing for high-grade non-mucinous carcinomas and mismatch repair protein testing for endometrioid and clear cell carcinomas, to inform patient management and identify Lynch syndrome.[9][12][13]
• Deliver holistic, timely and empathetic care, including sensitive communication, psychological support, specialist nursing, clear information about investigations and genetic testing, advance care planning and access to palliative care where appropriate.[9][8]

The guideline contributes to the National Cancer Strategy 2017-2026 priorities of prevention, early diagnosis, treatment and quality of life, in response to a substantial and increasing ovarian cancer burden.[14]It recognises projected growth in ovarian cancer cases of between 67% and 80% by 2045, requiring commensurate service and treatment capacity.[14]Professional judgement and patient preference may justify departure from a recommendation where appropriate, but the rationale should be recorded in the healthcare record.[1]

Implementation

Deliver the guideline through nationally coordinated, multidisciplinary cancer services, combining specialist diagnostic pathways, centralised surgical care, clinical governance, workforce development, implementation planning and audit.[5][15][16]The Health Service Executive implements recommendations with support from the National Cancer Control Programme, while corporate responsibility within hospitals rests with the Chief Executive Officer, General Manager and Clinical Director and discipline-specific responsibility rests with multidisciplinary team members.[1][17][18]

• Use the National Clinical Effectiveness Committee to prioritise, quality assure and recommend National Clinical Guidelines for Ministerial endorsement, with implementation through relevant service plans and alignment to national service-delivery priorities.[2][4]
• Coordinate specialist care through nine designated cancer centres, seven specialising in gynaecological oncology, supported by associated hospitals and the National Cancer Lead Clinicians Network for Surgical Gynaecology Oncology.[14]
• Review performance, improvement plans, workforce, resources, service development, multidisciplinary arrangements and service centralisation through regular engagement between the National Cancer Control Programme, cancer-centre senior management and Hospital Groups.[14][15]
• Use multidisciplinary team meetings to discuss indeterminate staging findings, suspected recurrence where appropriate, and treatment decisions, ensuring that clinical, imaging and pathology information informs management.[6][8][10]
• Maintain laboratory quality through participation in the Health Service Executive National Quality Improvement Programme and Faculty of Pathology procedures, accredited immunohistochemistry services, appropriate antibody panels and referral of complex testing to specialist accredited laboratories.[10][11]
• Build genetics capacity through access to cancer genetics expertise, genetics liaison nurses, trained oncology staff able to order tests and provide pre-test counselling, post-test counselling after relevant findings, and referral to genetic services where indicated.[12][19]
• Strengthen enabling capacity through Health Service Executive service planning for trained radiology and nursing staff, genetic testing and staffing, psychosocial services, immunohistochemistry capacity, workforce planning, capital investment and supporting information technology systems.[20][21][22][23][19]

Implementation should be guided by a plan developed using the National Clinical Effectiveness Committee Implementation Guide, specifying actions, lead responsibilities, timeframes, expected outcomes, barriers, enablers and verification methods.[15][24]Dissemination should use professional networks, National Clinical Effectiveness Committee and National Cancer Control Programme websites, patient organisations, hospital communications, education and implementation tools.[15][16]

Guideline development and updating use systematic evidence appraisal, structured clinical questions based on the population, intervention or exposure, comparison, outcomes and time framework, and the Grading of Recommendations Assessment, Development and Evaluation approach to judge evidence quality and recommendation strength.[18][25][26]Patients participate as full Guideline Development Group members, contributing to consideration of benefits, harms, preferences, values and practical patient-care requirements.[27]The National Cancer Control Programme should conduct periodic literature surveillance, with the guideline considered for review after three years and updates subject to National Clinical Effectiveness Committee approval.[28]

Assess delivery and impact through clinical audit of implementation and patient outcomes, applying Health Service Executive audit stages and relevant Cancer Strategy performance indicators.[15][29]Explicit audit areas include access to transvaginal ultrasound, genetic-testing resources and offers, patient information on genetic testing, and formal multidisciplinary discussion of invasive cancer cases.[20][29][30]

Monitoring & Evaluation

Implementation is overseen through clinical governance, corporate responsibility in hospitals and national programme structures, with audit and periodic review intended to assess whether the guideline improves care and patient outcomes.[1][15][16]

• Assign accountability to hospital Chief Executive Officers, General Managers and Clinical Directors, while requiring multidisciplinary team members to implement discipline-specific recommendations and record justified departures from recommendations in the healthcare record.[1][17][10]
• Monitor national guideline implementation and impact periodically, monitor individual, team and organisational performance, report on National Clinical Audit performance, and publish an annual National Clinical Effectiveness Committee report.[4]
• Use an implementation plan to define actions, leads, timeframes, expected outcomes, barriers, enablers and verification methods.[15][24]
• Review performance data, improvement plans, workforce and service-development issues through regular engagement between the National Cancer Control Programme, cancer centres, Hospital Groups and senior management.[14][15]
• Audit implementation and patient outcomes using the Health Service Executive five-stage process of planning, selecting criteria, measuring performance, improving care and sustaining improvement.[16][29]
• Measure access to transvaginal ultrasound for women with suspected ovarian cancer, genetic-testing resources and offers, and provision of genetic-testing information.[20][29]
• Track the target for 95% of invasive cancer cases to be formally discussed at a multidisciplinary team meeting by the end of 2020, and the National Cancer Strategy target for 95% of cancer surgery to occur in approved centres by 2020.[30][5]
• Verify implementation through trained staff, available diagnostic access, training records, workforce and capital plans, functioning information technology systems, patient information, psychological-support staff, radiology-reporting templates and immunohistochemistry capacity.[20][21][22][19]
• Require pathology laboratories to participate in the National Quality Improvement Programme and use accredited immunohistochemistry services, with compliance monitored through those arrangements.[10][11]
• Review the guideline after three years, conduct periodic literature surveillance, and record approved updates on National Cancer Control Programme and National Clinical Effectiveness Committee websites.[25][28]

Evidence assessment uses systematic literature review, Scottish Intercollegiate Guidelines Network appraisal tools and the Grading of Recommendations Assessment, Development and Evaluation approach, while national consultation feedback, modifications and supporting evidence are documented.[25][27][26]The source does not provide a single comprehensive indicator set, reporting timetable or surveillance protocol for all recommendations.[31][5][7]

Costing & Financing

Implementation is estimated to cost €12,350,579 in total, comprising €1,633,085 in operational costs and €10,717,494 in staff costs; the estimated total range is €12,260,156 to €12,385,965, based on projected ovarian cancer cases in 2020.[28]

• Estimate median 2020 implementation costs at €543,962 for operations, €3,572,498 for staff and €4,116,460 in total, based on 445 projected cases.[28]
• Apply Health Information and Quality Authority budget-impact-analysis assumptions of a 4% pension adjustment, 10.95% pay-related social insurance and 25% overheads in salary calculations.[28]
• Seek funding for cancer-surgery centralisation, additional implementation resources, radiology and nursing staff, psychological and immunohistochemistry staffing, and genetic testing and workforce expansion through Health Service Executive service-planning processes.[5][6][20][21][23][19]
• Use workforce planning, an annual rolling capital investment plan and identified resource issues in service planning to address delivery capacity.[14][20][22]
• Consider resource implications and cost in developing and grading recommendations, supported by a systematic review of cost-effectiveness.[3][25][24]
• Recognise limited economic evidence: only two of nine economic questions had relevant evidence, no published Irish cost-effectiveness evidence was identified for genetic testing, and international findings were contradictory.[24]

The National Cancer Control Programme commissioned and funded the guideline, with content intended to remain independent of the funder.[18]Wider context estimates put Irish cancer-related healthcare costs at €619 million and projected household-production losses from each premature ovarian cancer death at €367,284 by 2030.[3]Beyond the stated implementation estimate and service-planning routes, the source does not specify a dedicated funding allocation, budget owner or quantified funding gap.[24][28]